Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial

Biblos-e Archivo/Manakin Repository

Files in this item

Thumbnail
Share

Delicious Save this on Delicious

Citations

This item appears in the following Collection(s)